LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 31

Search options

  1. Thesis ; Online: Tuning of Human Mucosal Associated Invariant T (MAIT) Cell Function through Microbiota-Mediated T Cell Receptor Signals

    Tastan, Cihan

    2017  

    Abstract: Mucosal-associated invariant T (MAIT) cells are a subset of the T cell population defined by an invariant T cell receptor (TCR) that is stimulated by bacterial metabolites. These cells preferentially migrate to mucosal tissues such as gut, liver and skin. ...

    Abstract Mucosal-associated invariant T (MAIT) cells are a subset of the T cell population defined by an invariant T cell receptor (TCR) that is stimulated by bacterial metabolites. These cells preferentially migrate to mucosal tissues such as gut, liver and skin. MAIT cells are activated by metabolites from the riboflavin (Vitamin B2) biosynthetic pathway that are presented by MHC class 1-related (MR1) molecules expressed on numerous of cell types including antigen presenting cells (APCs) and epithelial cells. The V alpha segment of MAIT TCRs is invariant and composed of Vα7.2, whereas the V beta portion can be variable. MAIT cells are present at very low levels in neonatal blood but significantly increase in adults and show very high variance in their frequency among individuals. While there is evidence that several pathogenic bacteria can activate MAIT cells and that one of their functions is to kill cells with intracellular bacteria, it remains unknown how they discriminate among thousands of commensal bacteria that can also produce Vitamin B2 metabolites. Further, the role of the TCR variable beta region in antigen recognition is still unclear. In this thesis project, we hypothesized that MAIT cells can be stimulated by bacteria that inhabit human mucosal tissues, and that this microbiota-MAIT cell interaction is one of the driving forces in their expansion and variation in the human population. In support of this hypothesis, we observed a reduced proportion of MAIT cells in the blood of perinatally HIV-infected children, which correlated with other microbiota-associated parameters including Th17 cells and inflammatory markers of microbiota alterations. However, it is unclear whether MAIT cells can discriminate bacterial species that reside in the human microbiota, which can produce the riboflavin intermediates. To address this, we developed an in vitro functional assay using human T cells engineered for MAIT-specific TCRs (eMAIT-TCRs) stimulated by MR1-expressing B cell lines presenting the bacterial metabolites. We then screened 47 microbiota-associated bacterial species from different phyla for their eMAIT-TCR stimulatory capacities. Only bacterial species that encoded a riboflavin biosynthesis pathway were stimulatory for MAIT-TCRs. Most species that were high-stimulators belonged to Bacteroidetes and Proteobacteria phyla, although with significant variance, whereas low/non-stimulator species were either Actinobacteria or Firmicutes. Furthermore, we determined a wide range of intra-species variation in eMAIT-TCR stimulation capacities of Staphylococcus epidermidis , a skin commensal, which suggests that bacteria can modulate the production capacities of MAIT-TCR stimulatory antigens. Remarkably, we also discovered that human T cells not only express low-levels of MR1 but can also present bacterial metabolites to MAIT cells in an MR1-restricted fashion and trigger TCR signaling to induce cytokine secretion (IFNγ and TNFα), albeit at lower levels. In conclusion, our findings revealed that MAIT cells could discriminate between MR1-restricted, bacteria-derived metabolites through their TCR signaling thresholds. This knowledge paves the way to elucidate the complexity of MAIT cell recognition and its response to the human microbiota, which establishes a framework to explore mechanistic or therapeutic approaches for maintenance of a healthy immunological equilibrium.
    Keywords Microbiology|Immunology
    Subject code 610
    Language ENG
    Publishing date 2017-01-01 00:00:01.0
    Publisher New York University
    Publishing country us
    Document type Thesis ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article: CAR-T Cells with Phytohemagglutinin (PHA) Provide Anti-Cancer Capacity with Better Proliferation, Rejuvenated Effector Memory, and Reduced Exhausted T Cell Frequencies.

    Gulden, Gamze / Sert, Berranur / Teymur, Tarik / Ay, Yasin / Tiryaki, Nulifer Neslihan / Mishra, Abhinava K / Ovali, Ercument / Tarhan, Nevzat / Tastan, Cihan

    Vaccines

    2023  Volume 11, Issue 2

    Abstract: The development of genetic modification techniques has led to a new era in cancer treatments that have been limited to conventional treatments such as chemotherapy. intensive efforts are being performed to develop cancer-targeted therapies to avoid the ... ...

    Abstract The development of genetic modification techniques has led to a new era in cancer treatments that have been limited to conventional treatments such as chemotherapy. intensive efforts are being performed to develop cancer-targeted therapies to avoid the elimination of non-cancerous cells. One of the most promising approaches is genetically modified CAR-T cell therapy. The high central memory T cell (Tcm) and stem cell-like memory T cell (Tscm) ratios in the CAR-T cell population increase the effectiveness of immunotherapy. Therefore, it is important to increase the populations of CAR-expressing Tcm and Tscm cells to ensure that CAR-T cells remain long-term and have cytotoxic (anti-tumor) efficacy. In this study, we aimed to improve CAR-T cell therapy's time-dependent efficacy and stability, increasing the survival time and reducing the probability of cancer cell growth. To increase the sub-population of Tcm and Tscm in CAR-T cells, we investigated the production of a long-term stable and efficient cytotoxic CAR-T cell by modifications in the cell activation-dependent production using Phytohemagglutinin (PHA). PHA, a lectin that binds to the membranes of T cells and increases metabolic activity and cell division, is studied to increase the Tcm and Tscm population. Although it is known that PHA significantly increases Tcm cells, B-lymphocyte antigen CD19-specific CAR-T cell expansion, its anti-cancer and memory capacity has not yet been tested compared with aCD3/aCD28-amplified CAR-T cells. Two different types of CARs (aCD19 scFv CD8-(CD28 or 4-1BB)-CD3z-EGFRt)-expressing T cells were generated and their immunogenic phenotype, exhausted phenotype, Tcm-Tscm populations, and cytotoxic activities were determined in this study. The proportion of T cell memory phenotype in the CAR-T cell populations generated by PHA was observed to be higher than that of aCD3/aCD28-amplified CAR-T cells with similar and higher proliferation capacity. Here, we show that PHA provides long-term and efficient CAR-T cell production, suggesting a potential alternative to aCD3/aCD28-amplified CAR-T cells.
    Language English
    Publishing date 2023-01-31
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines11020313
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A

    Hemşinlioğlu, Cansu / Aslan, Elif Sibel / Taştan, Cihan / Çakırsoy, Didem / Turan, Raife Dilek / Seyis, Utku / Elek, Muhammer / Sır Karakuş, Gözde / Günaydın, Ömur Selin / Abanuz, Selen / Kançağı, Derya Dilek / Yurtsever, Bulut / Yalçın, Koray / Kasap, Murat / Ovalı, Ercüment

    Turkish journal of haematology : official journal of Turkish Society of Haematology

    2023  Volume 40, Issue 2, Page(s) 118–124

    Abstract: Objective: Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency of plasma coagulation factor VIII (FVIII), and it accounts for about 80%-85% of all cases of hemophilia. Plasma-derived therapies or recombinant FVIII concentrates ...

    Abstract Objective: Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency of plasma coagulation factor VIII (FVIII), and it accounts for about 80%-85% of all cases of hemophilia. Plasma-derived therapies or recombinant FVIII concentrates are used to prevent and treat the bleeding symptoms along with FVIII-mimicking antibodies. Recently, the European Medicines Agency granted conditional marketing approval for the first gene therapy for hemophilia A. The aim of this study was to determine the effectiveness of coagulation in correcting FVIII deficiency with FVIII-secreting transgenic mesenchymal stem cells (MSCs).
    Materials and methods: A lentiviral vector encoding a B domain-deleted FVIII cDNA sequence with CD45R0 truncated (CD45R0t) surface marker was designed to develop a transgenic FVIII-expressing primary cell line by transducing MSCs. The efficacy and functionality of the FVIII secreted from the MSCs was assessed with anti-FVIII ELISA, CD45R0t flow cytometry, FVIII western blot, and mixing test analysis in vitro.
    Results: The findings of this study showed that the transgenic MSCs maintained persistent FVIII secretion. There was no significant difference in FVIII secretion over time, suggesting stable FVIII expression from the MSCs. The functionality of the FVIII protein secreted in the MSC supernatant was demonstrated by applying a mixing test in coagulation analysis. In the mixing test analysis, FVIII-deficient human plasma products were mixed with either a saline control or FVIII-secreted MSC supernatant. The mean FVIII level of the saline control group was 0.41±0.03 IU/dL, whereas the mean level was 25.41±33.38 IU/dL in the FVIII-secreting MSC supernatant mixed group (p<0.01). The mean activated partial thromboplastin time (aPTT) of the saline control group was 92.69±11.38 s, while in the FVIII-secreting MSC supernatant mixed group, the mean aPTT level decreased to 38.60±13.38 s (p<0.001).
    Conclusion: The findings of this in vitro study suggest that the new method presented here is promising as a possible treatment for hemophilia A. Accordingly, a study of FVIII-secreting transgenic MSCs will next be initiated in a FVIII-knockout animal model.
    MeSH term(s) Animals ; Humans ; Factor VIII/genetics ; Hemophilia A/genetics ; Hemophilia A/therapy ; Blood Coagulation ; Genetic Therapy/methods ; Mesenchymal Stem Cells/metabolism
    Chemical Substances Factor VIII (9001-27-8)
    Language English
    Publishing date 2023-04-06
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 2185903-6
    ISSN 1308-5263 ; 1300-7777
    ISSN (online) 1308-5263
    ISSN 1300-7777
    DOI 10.4274/tjh.galenos.2023.2022-0318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.

    Eren, Selen Abanuz / Tastan, Cihan / Karadeniz, Kevser Buse / Turan, Raife Dilek / Cakirsoy, Didem / Kancagi, Derya Dilek / Yilmaz, Sevdican Ustun / Oztatlici, Mustafa / Oztatlici, Hulya / Ozer, Samed / Tumentemur, Gamze / Baykal, Ahmet Tarık / Ovali, Ercument

    Current gene therapy

    2023  Volume 23, Issue 4, Page(s) 304–315

    Abstract: Aim: Duchenne Muscular Dystrophy (DMD) results in a deficiency of dystrophin expression in patient muscle fibers, leading to progressive muscle degeneration. Treatment of DMD has undertaken current transformation with the advancement of novel gene ... ...

    Abstract Aim: Duchenne Muscular Dystrophy (DMD) results in a deficiency of dystrophin expression in patient muscle fibers, leading to progressive muscle degeneration. Treatment of DMD has undertaken current transformation with the advancement of novel gene therapy and molecular biology techniques, which are secure, well-tolerated, and effective therapeutic approaches.
    Introduction: DMD gene therapies have mainly focused on young DMD patients as in vivo animal model trials have been performed in 0-1-month DMD mice. However, it has not yet been answered how micro-dystrophin encoding lentiviral treatment affects Dystrophin expression and DMD symptoms in 10-month mdx mice.
    Methods: We planned to integrate the micro-Dystrophin gene sequence into the muscle cells by viral transfer, using micro-Dystrophin-encoding lentivirus to reduce the dystrophic pathology in late-stage dmd mice. The histopathological and physiological-functional regeneration activities of the lentiviralmicro- Dystrophin gene therapy methods were compared, along with changes in temporal Dystrophin expression and their functionality, toxicity, and gene expression level.
    Results: Here, we showed that the micro-dystrophin transgene transfers intramuscularly and intraperitoneally in late-stage dmd-mdx-4cv mice restored dystrophin expression in the skeletal and cardiac muscle (
    Conclusion: Consequently, this study suggests that patients in the late stages of muscular dystrophy can benefit from lentiviral micro-dystrophin gene therapies to present an improvement in dystrophic muscle pathology.
    MeSH term(s) Mice ; Animals ; Dystrophin/genetics ; Muscular Dystrophy, Duchenne/genetics ; Muscular Dystrophy, Duchenne/therapy ; Mice, Inbred mdx ; Genetic Therapy/methods ; Disease Models, Animal ; Muscle, Skeletal
    Chemical Substances Dystrophin
    Language English
    Publishing date 2023-04-11
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2146187-9
    ISSN 1875-5631 ; 1566-5232
    ISSN (online) 1875-5631
    ISSN 1566-5232
    DOI 10.2174/1566523223666230407091317
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The effect of coronavirus disease 2019 pneumonia on myocardial ischemia detected by single-photon emission computed tomography myocardial perfusion imaging.

    Bilge, Önder / Kömek, Halil / Kepenek, Ferat / Taştan, Ercan / Gündoğan, Cihan / Tatli, İsmail / Öztürk, Cansu / Akin, Halil / Işik, Ferhat / Kavak, Şeyhmus / Aslan, Burhan / Akyüz, Abdurrahman / Kanbal Çap, Neşe / Erdoğan, Emrah

    Nuclear medicine communications

    2022  Volume 43, Issue 7, Page(s) 756–762

    Abstract: Objective: We aimed to examine the effects of COVID-19 pneumonia on cardiac ischemia detected by myocardial perfusion imaging with single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients presenting with chest pain ...

    Abstract Objective: We aimed to examine the effects of COVID-19 pneumonia on cardiac ischemia detected by myocardial perfusion imaging with single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients presenting with chest pain and shortness of breath after recovery from COVID-19.
    Materials and method: Patients with a history of COVID-19 confirmed by reverse transcriptase-PCR test who underwent SPECT-MPI for the evaluation of ischemia with the complaints of chest pain and shortness of breath were screened for this study. Patients who underwent thorax CT during the acute period of the COVID-19 were included. Patients with and without pneumonia were determined based on computed tomographic criteria. The patients with a summed stress score of at least 4 on SPECT-MPI were considered to have abnormal MPI in terms of ischemia.
    Results: A total of 266 patients were included in the study. Sixty-five (24%) patients had ischemia findings on SPECT-MPI. Thorax CT showed pneumonia in 152 (57%) patients, and the patients were divided into two groups as pneumonia and nonpneumonia. Abnormal SPECT-MPI scores, which represented myocardial ischemia, were higher in the pneumonia group. Multivariate logistic regression analyses showed that the presence of hyperlipidemia and pneumonia on CT increased the risk of ischemia on SPECT-MPI (OR, 2.08; 95% CI, 1.08-3.99; P-value = 0.029; and OR, 2.90; 95% Cl, 1.52-5.54; P-value = 0.001, respectively).
    Conclusion: COVID-19 pneumonia was identified as an independent predictor of ischemia on SPECT-MPI. Symptoms including chest pain and shortness of breath in patients who have had COVID-19 pneumonia may be attributed to coronary ischemia.
    MeSH term(s) COVID-19/complications ; COVID-19/diagnostic imaging ; Chest Pain ; Coronary Artery Disease ; Dyspnea ; Humans ; Myocardial Ischemia/complications ; Myocardial Ischemia/diagnostic imaging ; Myocardial Perfusion Imaging/methods ; Tomography, Emission-Computed, Single-Photon/methods
    Language English
    Publishing date 2022-05-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 758141-5
    ISSN 1473-5628 ; 0143-3636
    ISSN (online) 1473-5628
    ISSN 0143-3636
    DOI 10.1097/MNM.0000000000001569
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The effect of prior COVID-19 infection on coronary microvascular dysfunction.

    Bilge, Önder / Çap, Murat / Kepenek, Ferat / Erdogan, Emrah / Tatlı, İsmail / Öztürk, Cansu / Taştan, Ercan / Gündoğan, Cihan / Işık, Ferhat / Okşul, Metin / Oktay, Mesut / Akın, Halil / Burak, Cengiz / Karahan, Mehmet Zülküf / Kömek, Halil / Tanboğa, İbrahim Halil

    Acta cardiologica

    2022  , Page(s) 1–6

    Abstract: Background: Thrombolysis in Myocardial Infarction Frame Count (TFC) is an index that provides a quantitative evaluation of coronary microvascular dysfunction. In this study, we aimed to examine the effect of COVID-19 infection on TFC in patients ... ...

    Abstract Background: Thrombolysis in Myocardial Infarction Frame Count (TFC) is an index that provides a quantitative evaluation of coronary microvascular dysfunction. In this study, we aimed to examine the effect of COVID-19 infection on TFC in patients admitted with chest pain and dyspnoea after COVID-19 disease and had abnormal findings in myocardial perfusion scintigraphy.
    Methods: For this single-center retrospective study, patients with and without a history of COVID-19 who were underwent coronary angiography for abnormal findings in myocardial perfusion scintigraphy between January 1, 2021 and June 30, 2021 were analysed. Patients were divided into two groups as patients with COVİD-19 history and those without. After exclusion criteria, patients with adequate angiographic monitoring and data were included in the study.
    Results: A total of 210 patients, 48 with a history of COVID-19, were included in the study. The mean age was ±55 10 years, and 122 (58%) patients were women. In patients with a history of COVID-19, TFC was significantly higher in the LAD (
    Conclusion: TFC may be elevated due to coronary microvascular dysfunction in patients with a history of COVID-19.
    Language English
    Publishing date 2022-04-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 390197-x
    ISSN 1784-973X ; 0001-5385
    ISSN (online) 1784-973X
    ISSN 0001-5385
    DOI 10.1080/00015385.2022.2067641
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model.

    Sert, Berranur / Gulden, Gamze / Teymur, Tarik / Ay, Yasin / Turan, Raife Dilek / Unaldi, Onur Mert / Guzenge, Elanur / Erdil, Hamza Emir / Isik, Sevim / Oz, Pinar / Bozkurt, Ilknur / Ozer, Samed / Yurdakul, Tahire / Kamali, Osman / Ovali, Ercument / Tarhan, Nevzat / Tastan, Cihan

    Cancer gene therapy

    2023  Volume 31, Issue 3, Page(s) 387–396

    Abstract: Chimeric antigen receptor T (CAR-T) cell therapy holds great promise as an innovative immunotherapeutic approach for cancer treatment. To optimize the production and application of CAR-T cells, we evaluated the in vivo stability and efficacy capacities ... ...

    Abstract Chimeric antigen receptor T (CAR-T) cell therapy holds great promise as an innovative immunotherapeutic approach for cancer treatment. To optimize the production and application of CAR-T cells, we evaluated the in vivo stability and efficacy capacities of CAR-T cells developed under different conditions. In this study, CAR-T cells were activated using Phytohemagglutinin (PHA) or anti-CD3&anti-CD28 and were compared in an in vivo CD19+B-cell cancer model in mouse groups. Our results demonstrated that CAR-T cells activated with PHA exhibited higher stability and anti-cancer efficacy compared to those activated with anti-CD3&anti-CD28. Specifically, CAR19BB-T cells activated with PHA exhibited continuous proliferation and long-term persistence without compromising their anti-cancer efficacy. Kaplan-Meier survival analysis revealed prolonged overall survival in the CAR-T cell-treated groups compared to the only tumor group. Furthermore, specific LTR-targeted RT-PCR analysis confirmed the presence of CAR-T cells in the treated groups, with significantly higher levels observed in the CAR19BB-T (PHA) group compared to other groups. Histopathological analysis of spleen, kidney, and liver tissue sections indicated reduced inflammation and improved tissue integrity in the CAR-T cell-treated groups. Our findings highlight the potential benefits of using PHA as a co-stimulatory method for CAR-T cell production, offering a promising strategy to enhance their stability and persistence. These results provide valuable insights for the development of more effective and enduring immunotherapeutic approaches for cancer treatment. CAR-T cells activated with PHA may offer a compelling therapeutic option for advancing cancer immunotherapy in clinical applications.
    MeSH term(s) Mice ; Animals ; Phytohemagglutinins/pharmacology ; T-Lymphocytes ; Leukemia/therapy ; Immunotherapy, Adoptive/methods ; Neoplasms ; CD28 Antigens ; Antigens, CD19 ; Receptors, Antigen, T-Cell
    Chemical Substances Phytohemagglutinins ; CD28 Antigens ; Antigens, CD19 ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2023-12-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 1212513-1
    ISSN 1476-5500 ; 0929-1903
    ISSN (online) 1476-5500
    ISSN 0929-1903
    DOI 10.1038/s41417-023-00709-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics.

    Berber, Burak / Aydin, Cihan / Kocabas, Fatih / Guney-Esken, Gulen / Yilancioglu, Kaan / Karadag-Alpaslan, Medine / Caliseki, Mehmet / Yuce, Melek / Demir, Sevda / Tastan, Cihan

    Gene therapy

    2020  Volume 28, Issue 6, Page(s) 290–305

    Abstract: The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9-13, Lancet 2020;395:497-506, N. Engl J Med 2020a;382:1199-207, ...

    Abstract The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9-13, Lancet 2020;395:497-506, N. Engl J Med 2020a;382:1199-207, Nature 2020;579:270-3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265-9, N. Engl J Med 2020;382:727-33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444-8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1-18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727-33, MedRxiv 2020a, Turkish J Biol 2020;44:192-202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.
    MeSH term(s) COVID-19/diagnosis ; COVID-19/therapy ; CRISPR-Cas Systems ; Gene Editing ; Humans ; Oligonucleotides, Antisense ; RNA Interference
    Chemical Substances Oligonucleotides, Antisense
    Language English
    Publishing date 2020-12-14
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1191036-7
    ISSN 1476-5462 ; 0969-7128
    ISSN (online) 1476-5462
    ISSN 0969-7128
    DOI 10.1038/s41434-020-00209-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: SPECT myocardial perfusion imaging identifies myocardial ischemia in patients with a history of COVID-19 without coronary artery disease.

    Çap, Murat / Bilge, Önder / Gündoğan, Cihan / Tatlı, İsmail / Öztürk, Cansu / Taştan, Ercan / Kepenek, Ferat / Işık, Ferhat / Okşul, Metin / Oktay, Mesut / Akyüz, Abdurrahman / Erdoğan, Emrah / Burak, Cengiz / Süleymanoğlu, Muhammed / Karagöz, Ali / Tanboğa, İbrahim Halil

    The international journal of cardiovascular imaging

    2021  Volume 38, Issue 2, Page(s) 447–456

    Abstract: We aimed to examine the effect of a history of COVID-19 on myocardial ischemia in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in patients who presented with shortness of breath and/or chest pain after recovery. ... ...

    Abstract We aimed to examine the effect of a history of COVID-19 on myocardial ischemia in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in patients who presented with shortness of breath and/or chest pain after recovery. For this single-center retrospective study, patients who presented at cardiology outpatient clinics and had SPECT-MPI were screened. A total of 1888 patients were included in the study, 340 of whom had a history of COVID-19. 64 patients with > 50% stenosis on coronary angiography were excluded from the study. The primary outcome of the study was abnormal MPI. In the study population, the median age was 56 (49-64 IQR) years, and 1127 (65%) of the patients were female. Abnormal MPI was detected in 77 patients (23%) in the COVID-19 group and in 244 patients (16%) in the non-COVID-19 group. After adjustment was performed for clinical predictors using Bayesian logistic regression, an important association was found between the presence of a confirmed prior COVID-19 infection and abnormal MPI (posterior median odds ratio, 1.70 [95% CrI, 1.20-2.40], risk difference, 9.6% [95% CrI, 1.8%, 19.7%]). In SPECT-MPI, ischemia rates were observed to be higher in COVID-19 group and it was found that a confirmed prior COVID-19 might predict of abnormal MPI.
    MeSH term(s) Bayes Theorem ; COVID-19/complications ; Coronary Angiography/methods ; Coronary Artery Disease/diagnostic imaging ; Female ; Humans ; Middle Aged ; Myocardial Ischemia/diagnostic imaging ; Myocardial Perfusion Imaging/methods ; Predictive Value of Tests ; Retrospective Studies ; SARS-CoV-2 ; Tomography, Emission-Computed, Single-Photon/methods
    Language English
    Publishing date 2021-11-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2055311-0
    ISSN 1875-8312 ; 1573-0743 ; 1569-5794 ; 0167-9899
    ISSN (online) 1875-8312 ; 1573-0743
    ISSN 1569-5794 ; 0167-9899
    DOI 10.1007/s10554-021-02477-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application

    Erdoğan, Ebru / Yalçın, Koray / Hemşinlioğlu, Cansu / Sezgin, Aslıhan / Seyis, Utku / Kançağı, Derya Dilek / Taştan, Cihan / Yurtsever, Bulut / Turan, Raife Dilek / Çakırsoy, Didem / Abanuz, Selen / Sır Karakuş, Gözde / Elek, Muhammer / Bekoz, Hüseyin Saffet / Gemici, Ali İhsan / Sargın, Deniz / Arat, Mutlu / Ferhanoğlu, Burhan / Pekgüç, Ebru /
    Örnek, Serdar / Büyüktaş, Deram / Birgen, Nur / Ratip, Siret / Ovalı, Ercüment

    Turkish journal of haematology : official journal of Turkish Society of Haematology

    2022  Volume 39, Issue 3, Page(s) 206–210

    Abstract: Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability ... ...

    Abstract Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability and sustainability. In this preliminary study, the results of the first production and clinical data of an academic CAR-T cell (ISIKOK-19) trial in Turkey are presented.
    Materials and methods: A pilot clinical trial (NCT04206943) designed to assess the safety and feasibility of ISIKOK-19 T-cell therapy for patients with relapsed and refractory CD19+ tumors was conducted and participating patients received ISIKOK-19 infusions between October 2019 and July 2021. The production data of the first 8 patients and the clinical outcome of 7 patients who received ISIKOK-19 cell infusions are presented in this study.
    Results: Nine patients were enrolled in the trial [5 with acute lymphoblastic leukemia (ALL) and 4 with non-Hodgkin lymphoma (NHL)], but only 7 patients could receive treatment. Two of the 3 participating ALL patients and 3 of the 4 NHL patients had complete/partial response (overall response rate: 72%). Four patients (57%) had CAR-T-related toxicities (cytokine release syndrome, CAR-T-related encephalopathy syndrome, and pancytopenia). Two patients were unresponsive and had progressive disease following CAR-T therapy. Two patients with partial response had progressive disease during follow-up.
    Conclusion: Production efficacy and fulfillment of the criteria of quality control were satisfactory for academic production. Response rates and toxicity profiles were also acceptable for this heavily pretreated/refractory patient group. ISIKOK-19 cells appear to be a safe, economical, and efficient treatment option for CD19+ tumors. However, the findings of this study need to be supported by the currently ongoing ISIKOK-19 clinical trial.
    MeSH term(s) Antigens, CD19 ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Lymphoma, Non-Hodgkin/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/etiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/therapeutic use ; Receptors, Chimeric Antigen ; Turkey/epidemiology
    Chemical Substances Antigens, CD19 ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2022-07-18
    Publishing country Turkey
    Document type Clinical Trial ; Journal Article
    ZDB-ID 2185903-6
    ISSN 1308-5263 ; 1300-7777
    ISSN (online) 1308-5263
    ISSN 1300-7777
    DOI 10.4274/tjh.galenos.2022.2022.0193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top